Evidence on clinical relevance of cardiovascular risk evaluation in the general population using cardio-specific biomarkers
Aldo Clerico, Martina Zaninotto, Claudio Passino, Nadia Aspromonte, Massimo Piepoli, Marco Migliardi, Marco Alfonso Perrone, Antonio Fortunato, Andrea Padoan, Angelo Testa, F Dellarole, Tommaso Trenti, Sergio Bernardini, Laura Sciacovelli, Furio Colivicchi, Domenico Gabrielli, Mario Plebani
Abstract
In recent years, the formulation of some immunoassays with high-sensitivity analytical performance allowed the accurate measurement of cardiac troponin I (cTnI) and T (cTnT) levels in reference subjects. Several studies have demonstrated the association between the risk of major cardiovascular events and cardiac troponin concentrations even for biomarker values within the reference intervals. High-sensitivity cTnI and cTnT methods (hs-cTn) enable to monitor myocardial renewal and remodelling, and to promptly identify patients at highest risk ofheart failure. An early and effective treatment of individuals at higher cardiovascular risk may revert the initial myocardial remodelling and slow down heart failure progression. Specific clinical trials should be carried out to demonstrate the efficacy and efficiency of the general population screening by means of cost-benefit analysis, in order to better identify individuals at higher risk for heart failure (HF) progression with hs-cTn methods.